Member countries of the World Health Organization (WHO) have agreed to support pricing transparency for medicines, vaccines and other health products.
Under the resolution, companies will share information regarding how much governments and other buyers are spending on health products.
Go deeper with GlobalData
WHO is also calling for enhanced transparency on pharmaceutical patents, clinical trial results and factors that act as price determinants across the value chain.
As part of the project, WHO’s secretariat will review the effect of transparency on affordability and availability of health products, including the impact of differential pricing.
A statement from WHO reads: “The aim is to help member states make more informed decisions when purchasing health products, negotiate more affordable prices and ultimately expand access to health products for the populations.”
A draft resolution sent to the WHO on 1 February 2019 called for pharmaceutical companies to disclose the cost of making drugs. However, many countries opposed this proposal.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTransparency campaign group Knowledge Ecology International (KEI) head James Love noted that the US, Japan and Switzerland supported drug pricing transparency proposals, but opposed R&D costs transparency. Germany, Sweden, Denmark and the UK opposed the majority of transparency proposals.
Love added: “The biggest achievement was the agreement that member states should ‘take appropriate measures to publicly share information on net prices,’ but there was also much more achieved, scattered throughout the document, in different paragraphs, on various transparency targets or topics.”
The resolution mandates that information on drug prices, sales, units sold, patents, public / private sector R&D costs and R&D subsidies will be collected and shared.
According to KEI, the largest failure of the negotiations was non-disclosure of clinical trial costs.
